People

Management & Governance

Grade: C+. CooperCompanies has functional governance on paper — separate Chair and CEO, 100% independent board, clawback, anti-hedging — but two activist campaigns in late 2025 forced an admission that the watchdogs were asleep on capital allocation. A cooperation agreement in December 2025 placed a Browning West-backed director on the board and put the Chair role in play. Incentives rewarded revenue growth without regard for ROIC or free cash flow, and insiders (most notably 30-year director Bob Weiss) sold over $100M of stock since 2019 while returns on capital deteriorated. The refresh is real but incomplete.

The People Running This Company

Five Named Executive Officers. The CEO came up through finance and ran CooperSurgical before the top job — which is exactly the unit activists argue has been starved for discipline. The rest of the team is functional but not glamorous: a career-insider CFO, a lawyer-turned-COO, and two divisional presidents recruited from banking and a competitor.

What matters for trust: Al White's background is the one to scrutinize. He was CEO of CooperSurgical (2015–2018) immediately before becoming corporate CEO — the exact unit activists say has destroyed capital with a cumulative ROIC below 5% on $4B of investment. Jana's public note puts it bluntly: the parent-company CEO is the person least equipped to critically re-underwrite CooperSurgical. Sheffield inherits the same scrutiny, having run CooperSurgical through the period the company now admits "is not as efficient as it should be."

Succession: There is no publicly named heir apparent. McBride has the breadth to serve as caretaker; Andrews has only been CFO five years. If the activists succeed in separating the businesses, Warner is the natural continuing CEO of a pure-play CooperVision.

What They Get Paid

CEO pay of $16.0M for FY2025 is in line with peer medical-device CEOs, but the pay-ratio and pay-versus-performance tension is unusually sharp for a company whose stock fell more than 30% over the measurement window.

Structure and issues:

• Roughly 93% of White's target comp and 83% for other NEOs is "performance-based," but until fiscal 2026 the three-year PSU metric was adjusted constant-currency EPS growth only. Revenue, EPS, and FCF drive the annual IPP. Neither ROIC nor TSR were incentive inputs.
• The FY23–FY25 PSU cycle paid out at the 200% maximum (on 11.1% EPS CAGR versus an 11% cap) — a result Browning West attacks as "growth at all costs," since EPS growth was partly delivered via acquisitions while FCF declined from $421M (2019) to $288M (2024).
• After the activist letters the OCC added a 25% weighting of three-year relative TSR to FY2026 long-term grants, benchmarked against the S&P 500 Healthcare Equipment Index. This is a direct response to the criticism and is the single most substantive governance concession.
• Pay-versus-performance math is stark: FY25 "Compensation Actually Paid" to the CEO was $1.77M versus $16.05M reported, because a collapsing stock mechanically revalued his unvested equity downward. Alignment with stockholders on the way down is working; alignment with value creation clearly was not.

Are They Aligned?

Ownership

Insider ownership is small — 2.08% for all directors and officers combined. There is no founder or promoter stake. The shareholder register is institution-dominated.

Insider buying vs selling

The most striking signal is that in the second half of calendar 2025, every insider on record was a buyer, not a seller. Ten open-market purchases totalled about $2.5M at prices from $65 to $84. The CEO personally bought 20,000 shares at an average cost of $74. Zero open-market sells appear in the last twelve months of Form 4 filings.

The Weiss problem

Bob Weiss has been a director for 30 years. He was CEO from 2007 to 2018 and Chairman until the 2025 activist campaigns. He remains on the board and the proxy still labels him independent. That label is a stretch. Weiss has sold over $100M of Cooper stock since 2019 — including $29M in December 2023 at $91.20 and another $12.7M in March 2023 at $84.43. He still owns 546,805 shares (about $35M at current prices), of which 257,860 are held in an estate planning trust.

Browning West's letter singled Weiss out directly: "Mr. Weiss has sold over $100 million of Cooper stock since 2019" while "presiding over several years of value destruction." The company has since named Colleen Jay incoming Chair and committed to seriously consider Rosebrough for Chair by end of 2026 — effectively a planned exit path for Weiss from the Chair role, though he remains a 2026 director nominee.

Dilution and capital allocation

FY2025 was share-friendly at the margin: Cooper repurchased $290M / 4.1M shares at an average $69.30. Over a longer frame the picture is worse. Browning West calculates roughly $4B deployed into CooperSurgical at a cumulative ROIC below 5%, and says the company could not articulate to them the ROIC on $1.7B of CooperVision capex from 2019 to 2024. No explicit ROIC gate in incentives means capital discipline was a soft constraint at best.

Related-party transactions

None disclosed for FY2025. The policy requires Audit Committee pre-approval, KPMG reviews controls, and the proxy specifically states "we have determined that there were no related party transactions requiring disclosure." This is a legitimate green flag.

Skin-in-the-game score

Why 4.5/10: the CEO holds roughly $16M in stock (plus 1.7M exercisable options); all insiders combined own 2.08%. Recent insider buying is a positive signal (worth about one point). Offsetting: no founder or promoter with a concentrated long-term stake, historical pattern of aggressive selling by the former CEO/Chairman, and until FY2026 incentive metrics did not require ROIC or TSR hurdles. The refreshed FY2026 plan adds TSR, worth another half point once performance-tested. If the board adds an ROIC gate, this score moves to 6.

Board Quality

Post-refresh, Cooper's board is nine directors — eight independent plus White as the only insider. Excluding Weiss, average independent tenure is about four years.

What the board is good at: finance and audit oversight (three former CFOs plus a former KPMG audit partner), separate Chair and CEO, no poison pill, majority voting standard, proxy access, annual self-evaluation with a third-party administrator, and committee independence.

What it's demonstrably not good at: operating expertise in the businesses Cooper actually runs. Until Rosebrough joined in January 2026, zero directors had operating experience in vision care or were medical-device CEOs with a track record of value creation. The CEO Al White himself serves on only one outside board (Evolus). Board members' secondary directorships skew consumer (Jay at Beyond Meat, Kurzius at Lamb Weston) rather than medical devices.

The Verdict

Strongest positives:

• Procedural hygiene is strong: independent Chair, fully independent committees, no poison pill, clawback, anti-hedging, double-trigger change-in-control, no tax gross-ups, no related-party transactions disclosed.
• Insiders put their own money down in 2H 2025. Eight buyers, zero open-market sellers in the most recent twelve months of Form 4s.
• The activist settlement produced a genuinely high-quality addition (Rosebrough delivered an 18% CAGR over fourteen years at STERIS) and, for FY2026, a new 25% relative-TSR PSU component that directly addresses one of the loudest criticisms.

Real concerns:

• The fact that two activists had to show up in the same quarter to get these changes is itself the verdict on board oversight. Browning West's claim is not that Cooper's governance policies are weak; it's that the board applied them to a strategy — growth at any cost in CooperSurgical — that was destroying capital and rewarded management for it.
• Weiss's 30-year tenure and documented selling pattern undermine the independence claim on paper. He remains a 2026 nominee.
• Until FY2026, incentive plans had no ROIC gate and no TSR test. The board approved a 200% PSU payout for the FY23–FY25 cycle during a period in which the stock underperformed its sector by more than 100 percentage points over five years.
• The CEO is the former head of the division activists want broken off. Any strategic review of CooperSurgical is awkward for him to lead credibly.

The one thing that moves the grade:

• Upgrade to B+ if Rosebrough is named Chair, Weiss retires by the 2027 annual meeting, an ROIC hurdle is added to incentive metrics, and the board publicly re-underwrites CooperSurgical's capital allocation.
• Downgrade to C if the cooperation agreement is the ceiling — Rosebrough is a single seat, Weiss stays on, and the FY2026 TSR metric is the only substantive comp reform.